[Polyarthritis and papular eruption revealing leprosy].
Leprosy is generally revealed by cutaneous lesions often associated to nerve impairment. Rarely, it may be revealed by polyarthritis. The diagnosis, often delayed in the cutaneous-nevritic form because of the low prevalence of the disease in metropolitan France, is very difficult in case of rheumatic presentation. We report the case of a 28 year-old woman from Mali, who was diagnosed with lepromatous borderline leprosy with reversal reaction occurring in the postpartum as she presented with polyarthritis and skin lesions.
Meyer
M
M
Service de dermatologie, centre hospitalier d'Argenteuil, 69, rue du lieutenant-colonel Prudhon, 95100 Argenteuil, France.
Ingen-Housz-Oro
S
S
Ighilahriz
O
O
Wendling
J
J
Gaulier
A
A
Levy-Weil
F
F
Sigal-Grinberg
M
M
Flageul
B
B
D000284:Administration, Oral; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use; D000328:Adult; D001168:Arthritis / Q000209:etiology*; D001706:Biopsy; D002991:Clofazimine / Q000008:administration & dosage / Q000627:therapeutic use; D003622:Dapsone / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007917:Leprostatic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D015439:Leprosy, Borderline / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D015440:Leprosy, Lepromatous / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use; D012867:Skin / Q000473:pathology; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D007917:Leprostatic Agents; D003622:Dapsone; D002991:Clofazimine; D012293:Rifampin